Free tool
Diagnostics stocks
We cover 10 companies grouped under the Diagnostics theme. The median market value in the group is $3.61B. Across the group, the median move over the past trading day is +3.97%. Price change over the past year runs from −27.3% to +174.1% across the middle 80 percent of the group, with a median of +78.1%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
10 of 150 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −10.74% |
| CAI | Caris Life Sciences, Inc. | $7.38B | Mid cap | −27.21% |
| BLLN | BillionToOne, Inc. | $4.72B | Mid cap | −8.14% |
| ADPT | Adaptive Biotechnologies Corporation | $4.19B | Mid cap | +107.18% |
| GRAL | GRAIL, Inc. | $3.69B | Mid cap | +150.69% |
| VCYT | Veracyte, Inc. Common Stock | $3.54B | Mid cap | +49.04% |
| CDNA | CareDx, Inc. | $2.63B | Mid cap | +298.43% |
| WGS | GeneDx Holdings Corp. | $2.61B | Mid cap | −28.28% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +107.86% |
| NEO | NeoGenomics, Inc. | $2.19B | Mid cap | +160.31% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.